MannKind to Present at Upcoming Investor Conferences

Rhea-AI Summary

MannKind Corporation (MNKD), a company specializing in inhaled therapeutic products for endocrine and orphan lung diseases, has announced its participation in two upcoming investor conferences. CEO Michael Castagna and CFO Chris Prentiss will present at:

- RBC Capital Markets 2025 Global Annual Healthcare Conference on Tuesday, May 20 at 8:00 a.m. ET

- Jefferies Global Healthcare Conference on Thursday, June 5 at 2:35 p.m. ET

Both conferences will be held in New York City. Live audio webcasts will be available on MannKind's investor relations website, with recordings accessible for approximately 90 days after the events.

News Market Reaction

-3.18%

1 alert

-3.18% News Effect

On the day this news was published, MNKD declined 3.18%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced its participation at the upcoming investor conferences. MannKind’s Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will share updates during the following investor conferences, both being held in New York City:

RBC Capital Markets 2025 Global Annual Healthcare Conference
Tuesday, May 20, 8:00 a.m. ET

Jefferies Global Healthcare Conference
Thursday, June 5, 2:35 p.m. ET

Links to the live audio webcast of the sessions will be available on MannKind Corporation’s website at: https://investors.mannkindcorp.com/events-and-presentations. Recorded versions will also be available on the website for approximately 90 days following the conference.

About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.

We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.

With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.

Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram.

For MannKind: 
Investor Relations
Ana Kapor
(818) 661-5000
Email: ir@mnkd.com 

Media Relations
Christie Iacangelo
(818) 292-3500
Email: media@mnkd.com 

FAQ

When is MannKind (MNKD) presenting at the RBC Capital Markets Healthcare Conference 2025?

MannKind will present at the RBC Capital Markets Healthcare Conference on Tuesday, May 20, 2025, at 8:00 a.m. ET in New York City.

Who will represent MannKind (MNKD) at the upcoming investor conferences?

CEO Michael Castagna, PharmD, and CFO Chris Prentiss will represent MannKind at the upcoming conferences.

Where can I watch MannKind's (MNKD) investor conference presentations?

Live audio webcasts will be available on MannKind's investor relations website at investors.mannkindcorp.com/events-and-presentations, with recordings available for approximately 90 days after the events.

What is MannKind Corporation's (MNKD) main business focus?

MannKind Corporation focuses on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases.